Proprotein convertase subtilisin/kexin type 9 (EC 3.4.21.-) (Neural apoptosis-regulated convertase 1) (NARC-1) (Proprotein convertase 9) (PC9) (Subtilisin/kexin-like protease PC9)
1_MGTVS 6_ SRRSW 11_ WPLPL 16_ LLLLL 21_ LLLGP 26_ AGARA 31_ QEDED 36_ GDYEE 41_ LVLAL 46_ RSEED 51_ GLAEA 56_ PEHGT 61_ TATFH 66_ RCAKD 71_ PWRLP 76_ GTYVV 81_ VLKEE 86_ THLSQ 91_ SERTA 96_ RRLQA 101_ QAARR 106_ GYLTK 111_ ILHVF 116_ HGLLP 121_ GFLVK 126_ MSGDL 131_ LELAL 136_ KLPHV 141_ DYIEE 146_ DSSVF 151_ AQSIP 156_ WNLER 161_ ITPPR 166_ YRADE 171_ YQPPD 176_ GGSLV 181_ EVYLL 186_ DTSIQ 191_ SDHRE 196_ IEGRV 201_ MVTDF 206_ ENVPE 211_ EDGTR 216_ FHRQA 221_ SKCDS 226_ HGTHL 231_ AGVVS 236_ GRDAG 241_ VAKGA 246_ SMRSL 251_ RVLNC 256_ QGKGT 261_ VSGTL 266_ IGLEF 271_ IRKSQ 276_ LVQPV 281_ GPLVV 286_ LLPLA 291_ GGYSR 296_ VLNAA 301_ CQRLA 306_ RAGVV 311_ LVTAA 316_ GNFRD 321_ DACLY 326_ SPASA 331_ PEVIT 336_ VGATN 341_ AQDQP 346_ VTLGT 351_ LGTNF 356_ GRCVD 361_ LFAPG 366_ EDIIG 371_ ASSDC 376_ STCFV 381_ SQSGT 386_ SQAAA 391_ HVAGI 396_ AAMML 401_ SAEPE 406_ LTLAE 411_ LRQRL 416_ IHFSA 421_ KDVIN 426_ EAWFP 431_ EDQRV 436_ LTPNL 441_ VAALP 446_ PSTHG 451_ AGWQL 456_ FCRTV 461_ WSAHS 466_ GPTRM 471_ ATAVA 476_ RCAPD 481_ EELLS 486_ CSSFS 491_ RSGKR 496_ RGERM 501_ EAQGG 506_ KLVCR 511_ AHNAF 516_ GGEGV 521_ YAIAR 526_ CCLLP 531_ QANCS 536_ VHTAP 541_ PAEAS 546_ MGTRV 551_ HCHQQ 556_ GHVLT 561_ GCSSH 566_ WEVED 571_ LGTHK 576_ PPVLR 581_ PRGQP 586_ NQCVG 591_ HREAS 596_ IHASC 601_ CHAPG 606_ LECKV 611_ KEHGI 616_ PAPQE 621_ QVTVA 626_ CEEGW 631_ TLTGC 636_ SALPG 641_ TSHVL 646_ GAYAV 651_ DNTCV 656_ VRSRD 661_ VSTTG 666_ STSEG 671_ AVTAV 676_ AICCR 681_ SRHLA 686_QASQE
1: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:17461796, PubMed:18197702, PubMed:18799458, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways